Investor Presentaiton slide image

Investor Presentaiton

R&D investor presentation Data from a phase 2a trial with Ziltivekimab indicate lowering of hsCRP, which is a marker for inflammation Data from a phase 2a trial in CKD stage 5 patients with inflammation Trial design of ongoing phase 2b (RESCUE) 7.5 mg Q4W (66 patients) 15 mg Q4W (66 patients) Placebo Ziltivekimab 2 mg 6 mg 20 mg N=61 12 16 16 17 % of patients CKD stage 3-5 hsCRP >2 mg/L 30 mg Q4W (66 patients) hsCRP<2.0 14.3 43.8 60.0 90.9* mg/L, Week 12 Placebo Q4W (66 patients) 24-week treatment Conclusions: Ziltivekimab effectively reduces C-reactive protein (CRP) in patients with CKD on dialysis Ziltivekimab substantially reduced markers of inflammation with a trend towards improving NT-proBNP without adversely affecting lipoprotein lipids, neutrophils or platelets SOURCE: https://www.ahajournals.org/doi/10.1161/circ.140.suppl 1.13727. Primary endpoint Reduction of inflammation measured as reduction in C- reactive protein Purpose/timing Determine a dose for a potential phase 3 CVOT Phase 2 results expected H2 2020 hsCRP: High sensitivity C-reactive protein; CKD: chronic kidney disease; NT-proBNP: N-terminal-pro hormone BNP; Q4W: intravenously every 4 weeks; CVOT: cardiovascular outcomes trial 28
View entire presentation